Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Cancer Causes Control. 2017 Sep 12;28(10):1053–1063. doi: 10.1007/s10552-017-0956-1

Table 2.

Odds ratios for lung cancer risk according to the quartiles of serum 25(OH)D concentrations

Serum 25(OH)D N
(cases)
N
(controls)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
P-trend
All lung cancer1
Quartile 14 (Ref.) 64 73 1.00 1.00 0.85
Quartile 2 74 75 1.13 (0.40-1.81) 1.11 (0.65-1.88)
Quartile 3 84 75 1.27 (0.81-2.00) 1.15 (0.69-1.90)
Quartile 4 76 75 1.16 (0.72-1.87) 1.06 (0.61-1.84)

Non-small-cell lung cancer2,3
Quartile 1 (Ref.) 43 73 1.00 1.00 0.78
Quartile 2 49 75 1.11 (0.66-1.87) 1.07 (0.61-1.88)
Quartile 3 54 75 1.22 (0.73-2.04) 1.05 (0.60-1.85)
Quartile 4 45 75 1.02 (0.60-1.73) 0.94 (0.52-1.69)

Adenocarcinoma2
Quartile 1 (Ref.) 39 73 1.00 1.00 0.81
Quartile 2 42 75 1.05 (0.61-1.80) 0.98 (0.55-1.76)
Quartile 3 50 75 1.25 (0.74-2.12) 1.05 (0.58-1.88)
Quartile 4 39 75 0.97 (0.56-1.68) 0.91 (0.49-1.68)

N, number of participants; OR, odds ratio; CI, confidence interval

1

Odds ratios were estimated by conditional logistic regression models, adjusted for race/ethnicity, BMI, CaD Trial allocations, serum retinol concentrations, and season of blood draw.

2

Odds ratios were estimated by unconditional logistic regression, adjusted for the covariates and matching factors (age and CT/OS status).

3

Non-small cell lung cancer included adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

4

Serum 25(OH)D concentrations cutoffs were Q1: <33.9, Q2: 33.9-<45.3, Q3: 45.3-<58.9, Q4: ≥58.9 nmol/L.